A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.

Article Details

Citation

Copy to clipboard

Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, Roden DM, Darbar D

A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.

J Am Coll Cardiol. 2012 Jan 3;59(1):49-56. doi: 10.1016/j.jacc.2011.08.061.

PubMed ID

22192668 [ View in PubMed

]

Abstract

OBJECTIVES: In this study, we evaluated the impact of 2 common beta1-adrenergic receptor (beta1-AR) polymorphisms (G389R and S49G) in response to ventricular rate control therapy in patients with atrial fibrillation (AF). BACKGROUND: Randomized studies have shown that ventricular rate control is an acceptable treatment strategy in patients with AF. However, identification of patients who will adequately respond to rate-control therapy remains a challenge. METHODS: We studied 543 subjects (63% men; age 61.8 +/- 14 years) prospectively enrolled in the Vanderbilt AF registry and managed with rate-control strategy. A "responder" displayed adequate ventricular rate control based on the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) criteria: average heart rate (HR) at rest

DrugBank Data that Cites this Article

Pharmaco-genomics

Drug	Interacting Gene/Enzyme	Allele name	Genotypes	Defining change(s)	Type(s)	Description	Details
Atenolol	Beta-1 adrenergic receptor Gene symbol: ADRB1 UniProt: P08588	---	(C;C) / (C;G)	G > C (rs1801253)	Effect Directly Studied	Patients with this genotype have a greater reduction in blood pressure with atenolol.	Details
Diltiazem	Beta-1 adrenergic receptor Gene symbol: ADRB1 UniProt: P08588	---	(G;G) / (C;G)	C > G (rs1801253)	Effect Directly Studied	Patients with this genotype require a lower dosage of diltiazem to achieve a favourable rate-control response when treating atrial fibrillation.	Details
Verapamil	Beta-1 adrenergic receptor Gene symbol: ADRB1 UniProt: P08588	---	(G;G) / (C;G)	G > C (rs1801253)	Effect Directly Studied	Patients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.	Details